Phase 2 AMETHYST findings show continued improvements in skin redness and clinician- and patient-reported outcomes with litifilimab.

Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.

October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.

Gaurav Singh, MD, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.

A 2026 study links Agent Orange exposure to higher odds of acral melanoma in US veterans, highlighting the importance of early detection.

Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.

Phase 2/3 data show sustained hair growth and favorable safety outcomes with oral VDPHL01 in men with androgenetic alopecia.

BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active psoriatic arthritis.